EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Essex Woodlands Management Inc.

Essex Woodlands Management Inc. reduced its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 24.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,169,857 shares of the company’s stock after selling 381,664 shares during the period. EyePoint Pharmaceuticals comprises 2.0% of Essex Woodlands Management Inc.’s investment portfolio, making the stock its 4th largest holding. Essex Woodlands Management Inc.’s holdings in EyePoint Pharmaceuticals were worth $8,715,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Franklin Resources Inc. raised its position in shares of EyePoint Pharmaceuticals by 3.1% during the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company’s stock worth $30,825,000 after acquiring an additional 125,519 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of EyePoint Pharmaceuticals by 24.8% in the fourth quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company’s stock valued at $28,334,000 after buying an additional 755,045 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of EyePoint Pharmaceuticals by 92.7% during the fourth quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company’s stock worth $27,620,000 after buying an additional 1,783,765 shares during the period. Geode Capital Management LLC grew its holdings in shares of EyePoint Pharmaceuticals by 28.3% during the fourth quarter. Geode Capital Management LLC now owns 1,538,902 shares of the company’s stock worth $11,467,000 after buying an additional 339,846 shares during the last quarter. Finally, Finepoint Capital LP raised its stake in EyePoint Pharmaceuticals by 57.1% during the 4th quarter. Finepoint Capital LP now owns 1,111,104 shares of the company’s stock valued at $8,278,000 after acquiring an additional 403,700 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Chardan Capital restated a “buy” rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. Finally, Citigroup initiated coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

EyePoint Pharmaceuticals Stock Performance

Shares of EYPT stock opened at $5.68 on Friday. EyePoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $21.26. The stock has a market cap of $390.38 million, a PE ratio of -2.84 and a beta of 1.39. The stock has a fifty day moving average price of $5.93 and a 200 day moving average price of $7.83.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The business had revenue of $11.60 million for the quarter, compared to analysts’ expectations of $11.02 million. As a group, equities research analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.